Indivior Pharmaceuticals annual current ratio
2021
2022
2023
2024
2025
Indivior Pharmaceuticals Current Ratio Growth & History (INDV)
Indivior Pharmaceuticals's current ratio was 0.71 for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.71 | −0.18 | −20.30% |
| 2024 | 2024-12-31 | 0.90 | −0.09 | −8.79% |
| 2023 | 2023-12-31 | 0.98 | −0.25 | −20.58% |
| 2022 | 2022-12-31 | 1.24 | −0.56 | −31.21% |
| 2021 | 2021-12-31 | 1.80 | — | — |
Indivior Pharmaceuticals quarterly current ratio
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.84 | −0.07 | −7.25% |
| Q1 2026 | 2026-03-31 | 0.86 | −0.02 | −2.55% |
| Q4 2025 | 2025-12-31 | 0.71 | −0.18 | −20.30% |
| Q3 2025 | 2025-09-30 | 0.96 | — | — |
| Q2 2025 | 2025-06-30 | 0.90 | — | — |
| Q1 2025 | 2025-03-31 | 0.88 | — | — |
| Q4 2024 | 2024-12-31 | 0.90 | −0.09 | −8.79% |
| Q4 2023 | 2023-12-31 | 0.98 | −0.25 | −20.58% |
| Q4 2022 | 2022-12-31 | 1.24 | — | — |
Indivior Pharmaceuticals current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Indivior Pharmaceuticals's current ratio decreased from 1.80 to 0.71, a change of −1.08. The latest reported quarter, Q2 2026, shows 0.84.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals source filings ↗